

# Steven J Frank

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/726170/publications.pdf>

Version: 2024-02-01

369  
papers

11,433  
citations

28274

55  
h-index

51608

86  
g-index

378  
all docs

378  
docs citations

378  
times ranked

11122  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. <i>BJU International</i> , 2012, 109, 22-29.	2.5	391
2	Long-Term Failure Patterns and Survival in a Randomized Dose-Escalation Trial for Prostate Cancer. Who Dies of Disease?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 1310-1317.	0.8	229
3	Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer. <i>European Urology</i> , 2015, 67, 460-467.	1.9	190
4	Association of Body Composition With Survival and Locoregional Control of Radiotherapy-Treated Head and Neck Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 2016, 2, 782.	7.1	185
5	Definitive radiation therapy for squamous cell carcinoma of the vagina. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 62, 138-147.	0.8	181
6	Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer – A case matched analysis. <i>Radiotherapy and Oncology</i> , 2016, 120, 48-55.	0.6	177
7	Prospective Risk-Adjusted [ <sup>18</sup> F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography Assessment of Radiation Response in Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2509-2515.	1.6	156
8	Effectiveness of robust optimization in intensity-modulated proton therapy planning for head and neck cancers. <i>Medical Physics</i> , 2013, 40, 051711.	3.0	135
9	Magnetic Resonance Imaging-Guided Adaptive Radiation Therapy: A “Game Changer” for Prostate Treatment?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 361-373.	0.8	132
10	An Assessment of Quality of Life Following Radical Prostatectomy, High Dose External Beam Radiation Therapy and Brachytherapy Iodine Implantation as Monotherapies for Localized Prostate Cancer. <i>Journal of Urology</i> , 2007, 177, 2151-2156.	0.4	129
11	Multifield Optimization Intensity Modulated Proton Therapy for Head and Neck Tumors: A Translation to Practice. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 846-853.	0.8	128
12	Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 1059-1065.	0.8	127
13	Risk of Late Toxicity in Men Receiving Dose-Escalated Hypofractionated Intensity Modulated Prostate Radiation Therapy: Results From a Randomized Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 1074-1084.	0.8	127
14	Reirradiation of Head and Neck Cancers With Proton Therapy: Outcomes and Analyses. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 30-41.	0.8	123
15	Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 1107-1114.	0.8	121
16	Long-Term Biochemical and Survival Outcome of 921 Patients Treated With I-125 Permanent Prostate Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 1433-1438.	0.8	120
17	Reduce in Variation and Improve Efficiency of Target Volume Delineation by a Computer-Assisted System Using a Deformable Image Registration Approach. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 1512-1521.	0.8	113
18	Proton Radiation Therapy for Head and Neck Cancer: A Review of the Clinical Experience to Date. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 292-302.	0.8	104

#	ARTICLE	IF	CITATIONS
19	Intensity modulated proton therapy (IMPT) – The future of IMRT for head and neck cancer. <i>Oral Oncology</i> , 2019, 88, 66-74.	1.5	103
20	Brachytherapy: Where Has It Gone?. <i>Journal of Clinical Oncology</i> , 2015, 33, 980-982.	1.6	102
21	Intensity-modulated proton therapy for nasopharyngeal carcinoma: Decreased radiation dose to normal structures and encouraging clinical outcomes. <i>Head and Neck</i> , 2016, 38, E1886-95.	2.0	102
22	Magnetic Resonance Image Guided Brachytherapy. <i>Seminars in Radiation Oncology</i> , 2014, 24, 181-191.	2.2	101
23	The MRI-Linear Accelerator Consortium: Evidence-Based Clinical Introduction of an Innovation in Radiation Oncology Connecting Researchers, Methodology, Data Collection, Quality Assurance, and Technical Development. <i>Frontiers in Oncology</i> , 2016, 6, 215.	2.8	100
24	Reirradiation of Head and Neck Cancers With Intensity Modulated Radiation Therapy: Outcomes and Analyses. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 1117-1131.	0.8	100
25	Patterns of Disease Recurrence Following Treatment of Oropharyngeal Cancer With Intensity Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 941-947.	0.8	99
26	Unilateral Radiotherapy for the Treatment of Tonsil Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 204-209.	0.8	94
27	Simple Carotid-Sparing Intensity-Modulated Radiotherapy Technique and Preliminary Experience for T1–2 Glottic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 455-461.	0.8	89
28	Outcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21st century. <i>Radiation Oncology</i> , 2013, 8, 21.	2.7	89
29	Proton Therapy for Head and Neck Cancers. <i>Seminars in Radiation Oncology</i> , 2018, 28, 53-63.	2.2	89
30	Spot-scanning beam proton therapy vs intensity-modulated radiation therapy for ipsilateral head and neck malignancies: A treatment planning comparison. <i>Medical Dosimetry</i> , 2013, 38, 390-394.	0.9	88
31	Clinical Outcomes and Patterns of Disease Recurrence After Intensity Modulated Proton Therapy for Oropharyngeal Squamous Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 360-367.	0.8	88
32	Beyond mean pharyngeal constrictor dose for beam path toxicity in non-target swallowing muscles: Dose–volume correlates of chronic radiation-associated dysphagia (RAD) after oropharyngeal intensity modulated radiotherapy. <i>Radiotherapy and Oncology</i> , 2016, 118, 304-314.	0.6	85
33	Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) Versus Conventionally Fractionated IMRT for Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2943-2949.	1.6	85
34	COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms. <i>Clinical Cancer Research</i> , 2019, 25, 5650-5662.	7.0	83
35	Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourable-risk prostate cancer undergoing active surveillance. <i>BJU International</i> , 2016, 117, 469-477.	2.5	81
36	Late rectal complications after prostate brachytherapy for localized prostate cancer. <i>Cancer</i> , 2009, 115, 1827-1839.	4.1	80

#	ARTICLE	IF	CITATIONS
37	Toward a model-based patient selection strategy for proton therapy: External validation of photon-derived normal tissue complication probability models in a head and neck proton therapy cohort. <i>Radiotherapy and Oncology</i> , 2016, 121, 381-386.	0.6	78
38	Proton Therapy Reduces Treatment-Related Toxicities for Patients with Nasopharyngeal Cancer: A Case-Match Control Study of Intensity-Modulated Proton Therapy and Intensity-Modulated Photon Therapy. <i>International Journal of Particle Therapy</i> , 2015, 2, 19-28.	1.8	76
39	Intensity-Modulated Radiotherapy for Cervical Node Squamous Cell Carcinoma Metastases From Unknown Head-and-Neck Primary Site: M. D. Anderson Cancer Center Outcomes and Patterns of Failure. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 1005-1010.	0.8	75
40	Quantification of Prostate and Seminal Vesicle Interfraction Variation During IMRT. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 813-820.	0.8	74
41	PTV-based IMPT optimization incorporating planning risk volumes vs robust optimization. <i>Medical Physics</i> , 2013, 40, 021709.	3.0	74
42	Intensity-modulated proton therapy and osteoradionecrosis in oropharyngeal cancer. <i>Radiotherapy and Oncology</i> , 2017, 123, 401-405.	0.6	73
43	Primary adenocarcinoma of the vagina not associated with diethylstilbestrol (DES) exposure. <i>Gynecologic Oncology</i> , 2007, 105, 470-474.	1.4	70
44	Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1823-1830.	1.6	70
45	Dose-volume correlates of mandibular osteoradionecrosis in Oropharynx cancer patients receiving intensity-modulated radiotherapy: Results from a case-matched comparison. <i>Radiotherapy and Oncology</i> , 2017, 124, 232-239.	0.6	69
46	Preliminary evaluation of multifield and single-field optimization for the treatment planning of spot-scanning proton therapy of head and neck cancer. <i>Medical Physics</i> , 2013, 40, 081709.	3.0	68
47	Declining use of brachytherapy for the treatment of prostate cancer. <i>Brachytherapy</i> , 2014, 13, 157-162.	0.5	67
48	ACR Appropriateness Criteria Prostate Cancer—Pretreatment Detection, Staging, and Surveillance. <i>Journal of the American College of Radiology</i> , 2013, 10, 83-92.	1.8	65
49	Outcomes of malignant tumors of the lacrimal apparatus. <i>Cancer</i> , 2011, 117, 2801-2810.	4.1	62
50	Magnetic Resonance Imaging of Glucose Uptake and Metabolism in Patients with Head and Neck Cancer. <i>Scientific Reports</i> , 2016, 6, 30618.	3.3	62
51	Dosimetric advantages of intensity-modulated proton therapy for oropharyngeal cancer compared with intensity-modulated radiation: A case-matched control analysis. <i>Medical Dosimetry</i> , 2016, 41, 189-194.	0.9	62
52	Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets. <i>Clinical Cancer Research</i> , 2023, 27, 852-864.	7.0	61
53	Urinary Side Effects and Complications After Permanent Prostate Brachytherapy: The MD Anderson Cancer Center Experience. <i>Urology</i> , 2009, 74, 601-605.	1.0	59
54	Towards Effective and Efficient Patient-Specific Quality Assurance for Spot Scanning Proton Therapy. <i>Cancers</i> , 2015, 7, 631-647.	3.7	59

#	ARTICLE	IF	CITATIONS
55	Quality Assurance Assessment of Diagnostic and Radiation Therapyâ€™Simulation CT Image Registration for Head and Neck Radiation Therapy: Anatomic Region of Interestâ€™based Comparison of Rigid and Deformable Algorithms. <i>Radiology</i> , 2015, 274, 752-763.	7.3	58
56	Outcomes for olfactory neuroblastoma treated with induction chemotherapy. <i>Head and Neck</i> , 2017, 39, 1671-1679.	2.0	57
57	Outcomes after radiotherapy for squamous cell carcinoma of the eyelid. <i>Cancer</i> , 2008, 112, 111-118.	4.1	56
58	Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 790-797.	0.8	56
59	Beam path toxicity in candidate organs-at-risk: Assessment of radiation emetogenesis for patients receiving head and neck intensity modulated radiotherapy. <i>Radiotherapy and Oncology</i> , 2014, 111, 281-288.	0.6	54
60	Prospective Qualitative and Quantitative Analysis of Real-Time Peer Review Quality Assurance Rounds Incorporating Direct Physical Examination for Head and Neck Cancer Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 532-540.	0.8	54
61	Is Androgen Deprivation Therapy Necessary in All Intermediate-Risk Prostate Cancer Patients Treated in the Dose Escalation Era?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 693-699.	0.8	51
62	Intravoxel incoherent motion imaging kinetics during chemoradiotherapy for human papillomavirus-associated squamous cell carcinoma of the oropharynx: preliminary results from a prospective pilot study. <i>NMR in Biomedicine</i> , 2015, 28, 1645-1654.	2.8	51
63	Imaging and clinical data archive for head and neck squamous cell carcinoma patients treated with radiotherapy. <i>Scientific Data</i> , 2018, 5, 180173.	5.3	51
64	Multidisciplinary Management of Lacrimal Sac/Nasolacrimal Duct Carcinomas. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2013, 29, 454-457.	0.8	50
65	The impact of radiographic retropharyngeal adenopathy in oropharyngeal cancer. <i>Cancer</i> , 2013, 119, 3162-3169.	4.1	49
66	A Multidisciplinary Orbit-Sparing Treatment Approach That Includes Proton Therapy for Epithelial Tumors of the Orbit and Ocular Adnexa. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 344-352.	0.8	49
67	Radiation-Related Alterations of Taste Function in Patients With Head and Neck Cancer: a Systematic Review. <i>Current Treatment Options in Oncology</i> , 2018, 19, 72.	3.0	49
68	A Novel MRI Marker for Prostate Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 5-8.	0.8	48
69	High symptom burden prior to radiation therapy for head and neck cancer: A patientâ€™reported outcomes study. <i>Head and Neck</i> , 2013, 35, 1490-1498.	2.0	48
70	A biochemical definition of cure after brachytherapy for prostate cancer. <i>Radiotherapy and Oncology</i> , 2020, 149, 64-69.	0.6	48
71	Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: A survey of practice patterns in the United States. <i>Brachytherapy</i> , 2007, 6, 2-8.	0.5	47
72	The Insurance Approval Process for Proton Radiation Therapy: A Significant Barrier to Patient Care. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 724-733.	0.8	47

#	ARTICLE	IF	CITATIONS
73	MR Imaging of Prostate Cancer in Radiation Oncology: What Radiologists Need to Know. <i>Radiographics</i> , 2013, 33, 741-761.	3.3	46
74	Eye-sparing multidisciplinary approach for the management of lacrimal gland carcinoma. <i>Head and Neck</i> , 2016, 38, 1258-1262.	2.0	46
75	Postoperative Adjuvant External-Beam Radiation Therapy for Cancers of the Eyelid and Conjunctiva. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2008, 24, 444-449.	0.8	45
76	Prostate Specific Antigen Bounce Is Related to Overall Survival in Prostate Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 883-888.	0.8	45
77	Communicating Value in Health Care Using Radar Charts: A Case Study of Prostate Cancer. <i>Journal of Oncology Practice</i> , 2016, 12, 813-820.	2.5	44
78	Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation. <i>Cancer</i> , 2013, 119, 3265-3271.	4.1	43
79	Establishing High-Quality Prostate Brachytherapy Using a Phantom Simulator Training Program. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 579-586.	0.8	43
80	Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 374-382.	0.8	42
81	The role of elective nodal irradiation for esthesioneuroblastoma patients with clinically negative neck. <i>Practical Radiation Oncology</i> , 2016, 6, 241-247.	2.1	41
82	Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy (MR-ADAPTOR): An R-IDEAL stage 2a-2b/Bayesian phase II trial. <i>Clinical and Translational Radiation Oncology</i> , 2018, 13, 19-23.	1.7	41
83	Early experience with intensity modulated proton therapy for lung-intact mesothelioma: A case series. <i>Practical Radiation Oncology</i> , 2015, 5, e345-e353.	2.1	40
84	Health-Related Quality of Life up to Six Years After <sup>125</sup> I Brachytherapy for Early-Stage Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 1054-1060.	0.8	39
85	Assessing head and neck cancer patient preferences and expectations: A systematic review. <i>Oral Oncology</i> , 2016, 62, 44-53.	1.5	39
86	Quality of Life and Toxicity From Passively Scattered and Spot-Scanning Proton Beam Therapy for Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 946-953.	0.8	38
87	Magnetic resonance imaging-based treatment planning for prostate brachytherapy. <i>Brachytherapy</i> , 2013, 12, 30-37.	0.5	37
88	Defining the value framework for prostate brachytherapy using patient-centered outcome metrics and time-driven activity-based costing. <i>Brachytherapy</i> , 2016, 15, 274-282.	0.5	37
89	Focal MRI-Guided Salvage High-Dose-Rate Brachytherapy in Patients With Radiorecurrent Prostate Cancer. <i>Technology in Cancer Research and Treatment</i> , 2017, 16, 1194-1201.	1.9	37
90	Definitive proton radiation therapy and concurrent cisplatin for unresectable head and neck adenoid cystic carcinoma: A series of 9 cases and a critical review of the literature. <i>Head and Neck</i> , 2016, 38, E1472-80.	2.0	36

#	ARTICLE	IF	CITATIONS
91	Technology Insight: PET and PET/CT in head and neck tumor staging and radiation therapy planning. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 526-533.	4.3	34
92	Improvement in Prostate Cancer Survival Over Time. <i>Cancer Journal (Sudbury, Mass )</i> , 2012, 18, 1-8.	2.0	34
93	Comparative analysis of acute toxicities and patient reported outcomes between intensity-modulated proton therapy (IMPT) and volumetric modulated arc therapy (VMAT) for the treatment of oropharyngeal cancer. <i>Radiotherapy and Oncology</i> , 2020, 147, 64-74.	0.6	34
94	Positive Sentinel Node in Sebaceous Carcinoma of the Eyelid. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2011, 27, e4-e6.	0.8	33
95	Long-term outcomes after multidisciplinary management of T3 laryngeal squamous cell carcinomas: Improved functional outcomes and survival with modern therapeutic approaches. <i>Head and Neck</i> , 2016, 38, 1739-1751.	2.0	33
96	Proton therapy for nasopharyngeal carcinoma. <i>Chinese Clinical Oncology</i> , 2016, 5, 25-25.	1.2	33
97	Merkel cell carcinoma of the head and neck: Favorable outcomes with radiotherapy. <i>Head and Neck</i> , 2016, 38, E452-8.	2.0	32
98	Prospective observer and software-based assessment of magnetic resonance imaging quality in head and neck cancer: Should standard positioning and immobilization be required for radiation therapy applications?. <i>Practical Radiation Oncology</i> , 2015, 5, e299-e308.	2.1	31
99	Design and fabrication of a 3D-printed oral stent for head and neck radiotherapy from routine diagnostic imaging. <i>3D Printing in Medicine</i> , 2017, 3, 12.	3.1	31
100	Risk of second primary malignancies in head and neck cancer patients treated with definitive radiotherapy. <i>Npj Precision Oncology</i> , 2019, 3, 22.	5.4	31
101	Prognostic factors in adenocarcinoma of the salivary glands. <i>Oral Oncology</i> , 2015, 51, 610-615.	1.5	30
102	Creating customized oral stents for head and neck radiotherapy using 3D scanning and printing. <i>Radiation Oncology</i> , 2019, 14, 148.	2.7	30
103	Proton Beam Radiation Therapy for Head and Neck Malignancies. <i>Current Oncology Reports</i> , 2010, 12, 202-207.	4.0	29
104	Treatment planning for lung cancer: Traditional homogeneous point-dose prescription compared with heterogeneity-corrected dose-volume prescription. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 56, 1308-1318.	0.8	28
105	Results of the 2003 Association of Residents in Radiation Oncology (ARRO) surveys of residents and chief residents in the United States. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 642-648.	0.8	28
106	American College of Radiology Appropriateness Criteria permanent source brachytherapy for prostate cancer. <i>Brachytherapy</i> , 2011, 10, 357-362.	0.5	28
107	Auto-segmentation of low-risk clinical target volume for head and neck radiation therapy. <i>Practical Radiation Oncology</i> , 2014, 4, e31-e37.	2.1	28
108	Prognostic value of p16 expression in Epstein-Barr virus-positive nasopharyngeal carcinomas. <i>Head and Neck</i> , 2016, 38, E1459-66.	2.0	28

#	ARTICLE	IF	CITATIONS
109	Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy. <i>Cancer</i> , 2019, 125, 1823-1829.	4.1	28
110	Multiple-CT optimization: An adaptive optimization method to account for anatomical changes in intensity-modulated proton therapy for head and neck cancers. <i>Radiotherapy and Oncology</i> , 2020, 142, 124-132.	0.6	28
111	Outcomes of oral cavity cancer patients treated with surgery followed by postoperative intensity modulated radiation therapy. <i>Oral Oncology</i> , 2017, 72, 90-97.	1.5	28
112	Caspase-8 loss radiosensitizes head and neck squamous cell carcinoma to SMAC mimetic-induced necroptosis. <i>JCI Insight</i> , 2020, 5, .	5.0	28
113	Management of Perineural Invasion in Sebaceous Carcinoma of the Eyelid. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2011, 27, 356-359.	0.8	27
114	Management of the lymph node-positive neck in the patient with human papillomavirus-associated oropharyngeal cancer. <i>Cancer</i> , 2014, 120, 3082-3088.	4.1	27
115	Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. <i>BJU International</i> , 2016, 118, 68-76.	2.5	27
116	Patient-reported Urinary, Bowel, and Sexual Function After Hypofractionated Intensity-modulated Radiation Therapy for Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 558-567.	1.3	27
117	Comparing Intensity-Modulated Proton Therapy With Intensity-Modulated Photon Therapy for Oropharyngeal Cancer: The Journey From Clinical Trial Concept to Activation. <i>Seminars in Radiation Oncology</i> , 2018, 28, 108-113.	2.2	26
118	The Emerging Potential of Multi-Ion Radiotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 624786.	2.8	26
119	Low dose rate brachytherapy for primary treatment of localized prostate cancer: A systemic review and executive summary of an evidence-based consensus statement. <i>Brachytherapy</i> , 2021, 20, 1114-1129.	0.5	26
120	Intensity-Modulated Proton Therapy Adaptive Planning for Patients with Oropharyngeal Cancer. <i>International Journal of Particle Therapy</i> , 2017, 4, 26-34.	1.8	26
121	Comparative costs of advanced proton and photon radiation therapies: lessons from time-driven activity-based costing in head and neck cancer. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 297-301.	1.4	25
122	Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients ≥65 years old. <i>Radiation Oncology</i> , 2017, 12, 150.	2.7	25
123	Eye-Preserving Surgery Followed by Adjuvant Radiotherapy for Lacrimal Gland Carcinoma: Outcomes in 37 Patients. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2018, 34, 570-574.	0.8	25
124	Outcomes of carotid-sparing IMRT for T1 glottic cancer: Comparison with conventional radiation. <i>Laryngoscope</i> , 2020, 130, 146-153.	2.0	25
125	Outcomes after prostate brachytherapy are even better than predicted. <i>Cancer</i> , 2012, 118, 839-847.	4.1	24
126	PSA Response to Neoadjuvant Androgen Deprivation Therapy Is a Strong Independent Predictor of Survival in High-Risk Prostate Cancer in the Dose-Escalated Radiation Therapy Era. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, e39-e46.	0.8	24

#	ARTICLE	IF	CITATIONS
127	A single-field integrated boost treatment planning technique for spot scanning proton therapy. <i>Radiation Oncology</i> , 2014, 9, 202.	2.7	24
128	ACR Appropriateness Criteria high-dose-rate brachytherapy for prostate cancer. <i>Brachytherapy</i> , 2014, 13, 27-31.	0.5	24
129	Human papillomavirus status and the relative biological effectiveness of proton radiotherapy in head and neck cancer cells. <i>Head and Neck</i> , 2017, 39, 708-715.	2.0	24
130	Advances in Prostate Cancer Magnetic Resonance Imaging and Positron Emission Tomography-Computed Tomography for Staging and Radiotherapy Treatment Planning. <i>Seminars in Radiation Oncology</i> , 2017, 27, 21-33.	2.2	24
131	Chronic radiation-associated dysphagia in oropharyngeal cancer survivors: Towards age-adjusted dose constraints for deglutitive muscles. <i>Clinical and Translational Radiation Oncology</i> , 2019, 18, 16-22.	1.7	24
132	Prospective quantitative quality assurance and deformation estimation of MRI-CT image registration in simulation of head and neck radiotherapy patients. <i>Clinical and Translational Radiation Oncology</i> , 2019, 18, 120-127.	1.7	24
133	Proton versus photon radiation-induced cell death in head and neck cancer cells. <i>Head and Neck</i> , 2019, 41, 46-55.	2.0	23
134	Reduced acute toxicity and improved efficacy from intensity-modulated proton therapy (IMPT) for the management of head and neck cancer. <i>Chinese Clinical Oncology</i> , 2016, 5, 54-54.	1.2	23
135	Results of the 2004 Association of Residents in Radiation Oncology (ARRO) Survey. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 1199-1203.	0.8	22
136	The Impact of Acute Urinary Retention After Iodine-125 Prostate Brachytherapy on Health-Related Quality of Life. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 1322-1328.	0.8	22
137	An MRI-based dose-response analysis of urinary sphincter dose and urinary morbidity after brachytherapy for prostate cancer in a phase II prospective trial. <i>Brachytherapy</i> , 2013, 12, 210-216.	0.5	22
138	Impact of Insurance Status on Radiation Treatment Modality Selection Among Potential Candidates for Prostate, Breast, or Gynecologic Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 968-975.	0.8	22
139	Disease control and toxicity outcomes for T4 carcinoma of the nasopharynx treated with intensity-modulated radiotherapy. <i>Head and Neck</i> , 2016, 38, E925-33.	2.0	22
140	Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort. <i>BJU International</i> , 2018, 121, 540-548.	2.5	22
141	Prospective Imaging Assessment of Mortality Risk After Head-and-Neck Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 667-674.	0.8	21
142	Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: Implications for prostate brachytherapy. <i>Brachytherapy</i> , 2013, 12, 204-209.	0.5	21
143	MRI characterization of cobalt dichloride-N-acetyl cysteine (C4) contrast agent marker for prostate brachytherapy. <i>Physics in Medicine and Biology</i> , 2014, 59, 2505-2516.	3.0	21
144	Favorable patient reported outcomes following IMRT for early carcinomas of the tonsillar fossa: Results from a symptom assessment study. <i>Radiotherapy and Oncology</i> , 2015, 117, 132-138.	0.6	21

#	ARTICLE	IF	CITATIONS
145	Magnetic resonance imaging of swallowing-related structures in nasopharyngeal carcinoma patients receiving IMRT: Longitudinal dose-response characterization of quantitative signal kinetics. <i>Radiotherapy and Oncology</i> , 2016, 118, 315-322.	0.6	21
146	Long-term economic value of hypofractionated prostate radiation: Secondary analysis of a randomized trial. <i>Advances in Radiation Oncology</i> , 2017, 2, 249-258.	1.2	21
147	Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 7078-7088.	7.0	21
148	Xerostomia-related quality of life for patients with oropharyngeal carcinoma treated with proton therapy. <i>Radiotherapy and Oncology</i> , 2020, 142, 133-139.	0.6	21
149	Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends. <i>Cancer</i> , 2020, 126, 506-514.	4.1	21
150	Patient-reported outcomes, physician-reported toxicities, and treatment outcomes in a modern cohort of patients with sinonasal cancer treated using proton beam therapy. <i>Radiotherapy and Oncology</i> , 2020, 148, 258-266.	0.6	21
151	Risk Factors and Prognosis for Myoepithelial Carcinoma of the Major Salivary Glands. <i>Annals of Surgical Oncology</i> , 2015, 22, 3701-3707.	1.5	20
152	Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, 439-447.	2.0	20
153	Proton and photon radiosensitization effects of niraparib, a PARP inhibitor, on human head and neck cancer cells. <i>Head and Neck</i> , 2020, 42, 2244-2256.	2.0	20
154	Spot-Scanning Proton Therapy Patient-Specific Quality Assurance: Results from 309 Treatment Plans. <i>International Journal of Particle Therapy</i> , 2014, 1, 711-720.	1.8	20
155	Correlation of American Joint Committee on Cancer T Category for Eyelid Carcinoma With Outcomes in Patients With Periocular Merkel Cell Carcinoma. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2014, 30, 480-485.	0.8	19
156	Assessing the Quality of a Radiation Oncology Case-Based, Peer-Review Program in an Integrated Academic and Community Cancer Center Network. <i>Journal of Oncology Practice</i> , 2016, 12, e476-e486.	2.5	19
157	Patient reported dry mouth: Instrument comparison and model performance for correlation with quality of life in head and neck cancer survivors. <i>Radiotherapy and Oncology</i> , 2018, 126, 75-80.	0.6	19
158	Prognostic factors and survival in adenoid cystic carcinoma of the sinonasal cavity. <i>Head and Neck</i> , 2018, 40, 2596-2605.	2.0	19
159	Radiographic retropharyngeal lymph node involvement in HPV-associated oropharyngeal carcinoma: Patterns of involvement and impact on patient outcomes. <i>Cancer</i> , 2019, 125, 1536-1546.	4.1	19
160	Influence of Geography on Prostate Cancer Treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1286-1295.	0.8	19
161	Nomogram for Predicting Symptom Severity during Radiation Therapy for Head and Neck Cancer. <i>Otolaryngology - Head and Neck Surgery</i> , 2014, 151, 619-626.	1.9	18
162	Quantitative pretreatment CT volumetry: Association with oncologic outcomes in patients with T4a squamous carcinoma of the larynx. <i>Head and Neck</i> , 2017, 39, 1609-1620.	2.0	18

#	ARTICLE	IF	CITATIONS
163	Prognostic impact of leukocyte counts before and during radiotherapy for oropharyngeal cancer. <i>Clinical and Translational Radiation Oncology</i> , 2017, 7, 28-35.	1.7	18
164	Outcomes of patients diagnosed with carcinoma metastatic to the neck from an unknown primary source and treated with intensity-modulated radiation therapy. <i>Cancer</i> , 2018, 124, 1415-1427.	4.1	18
165	Significance of Negative Posttreatment 18-FDG PET/CT Imaging in Patients With p16/HPV-Positive Oropharyngeal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1029-1035.	0.8	18
166	MRI guided focal HDR brachytherapy for localized prostate cancer: Toxicity, biochemical outcome and quality of life. <i>Radiotherapy and Oncology</i> , 2018, 129, 554-560.	0.6	18
167	Machine Segmentation of Pelvic Anatomy in MRI-Assisted Radiosurgery (MARS) for Prostate Cancer Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 1292-1303.	0.8	18
168	Association of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate Cancer. <i>JAMA Network Open</i> , 2020, 3, e201255.	5.9	18
169	Proton Reirradiation: Expert Recommendations for Reducing Toxicities and Offering New Chances of Cure in Patients With Challenging Recurrence Malignancies. <i>Seminars in Radiation Oncology</i> , 2020, 30, 253-261.	2.2	18
170	Lymphopenia during radiotherapy in patients with oropharyngeal cancer. <i>Radiotherapy and Oncology</i> , 2020, 145, 95-100.	0.6	18
171	Intensity-modulated proton therapy for oropharyngeal cancer reduces rates of late xerostomia. <i>Radiotherapy and Oncology</i> , 2021, 160, 32-39.	0.6	18
172	Comprehensive Quantitative Evaluation of Variability in Magnetic Resonance-Guided Delineation of Oropharyngeal Gross Tumor Volumes and High-Risk Clinical Target Volumes: An R-IDEAL Stage 0 Prospective Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 426-436.	0.8	18
173	Radiation therapy (with or without neck surgery) for phenotypic human papillomavirus-associated oropharyngeal cancer. <i>Cancer</i> , 2016, 122, 1702-1707.	4.1	17
174	Quantitative analysis of treatment process time and throughput capacity for spot scanning proton therapy. <i>Medical Physics</i> , 2016, 43, 3975-3986.	3.0	17
175	A methodology to investigate the impact of image distortions on the radiation dose when using magnetic resonance images for planning. <i>Physics in Medicine and Biology</i> , 2018, 63, 085005.	3.0	17
176	Long-term quality of life after definitive treatment of sinonasal and nasopharyngeal malignancies. <i>Laryngoscope</i> , 2020, 130, 86-93.	2.0	17
177	Malignant Mixed Tumor (Carcinoma Ex Pleomorphic Adenoma) of the Lacrimal Gland. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2020, 36, 497-502.	0.8	17
178	Prognostic significance of pre-treatment neutrophil-to-lymphocyte ratio (NLR) in patients with oropharyngeal cancer treated with radiotherapy. <i>British Journal of Cancer</i> , 2021, 124, 628-633.	6.4	17
179	Variations in proton scanned beam dose delivery due to uncertainties in magnetic beam steering. <i>Medical Physics</i> , 2009, 36, 3693-3702.	3.0	16
180	Prostate cancer-specific mortality after definitive radiation therapy: Who dies of disease?. <i>European Journal of Cancer</i> , 2012, 48, 1664-1671.	2.8	16

#	ARTICLE	IF	CITATIONS
181	A Biodistribution and Toxicity Study of Cobalt Dichloride-N-Acetyl Cysteine in an Implantable MRI Marker for Prostate Cancer Treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 1024-1030.	0.8	16
182	Improving prostate brachytherapy quality assurance with MRIâ€“CT fusionâ€“based sector analysis in a phase II prospective trial of men with intermediate-risk prostate cancer. <i>Brachytherapy</i> , 2013, 12, 401-407.	0.5	16
183	Development of a magnetic resonance imaging protocol to visualize encapsulated contrast agent markers in prostate brachytherapy recipients: initial patient experience. <i>Journal of Contemporary Brachytherapy</i> , 2016, 3, 233-240.	0.9	16
184	Recurrent oral cavity cancer: Patterns of failure after salvage multimodality therapy. <i>Head and Neck</i> , 2017, 39, 633-638.	2.0	16
185	Quantifying institutional resource utilization of adjuvant brachytherapy and intensity-modulated radiation therapy for endometrial cancer via time-driven activity-based costing. <i>Brachytherapy</i> , 2019, 18, 445-452.	0.5	16
186	Quantifying the accuracy of deformable image registration for coneâ€“beam computed tomography with a physical phantom. <i>Journal of Applied Clinical Medical Physics</i> , 2019, 20, 92-100.	1.9	16
187	Fatigue following radiation therapy in nasopharyngeal cancer survivors: A dosimetric analysis incorporating patient report and observer rating. <i>Radiotherapy and Oncology</i> , 2019, 133, 35-42.	0.6	16
188	Postoperative Intensity-Modulated Proton Therapy for Head and Neck Adenoid Cystic Carcinoma. <i>International Journal of Particle Therapy</i> , 2016, 2, 533-543.	1.8	16
189	Is a Loose-Seed Nomogram Still Valid for Prostate Brachytherapy in a Stranded-Seed Era?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 623-627.	0.8	15
190	Effect of pulse sequence parameter selection on signal strength in positiveâ€“contrast MRI markers for MRIâ€“based prostate postimplant assessment. <i>Medical Physics</i> , 2016, 43, 4312-4322.	3.0	15
191	Use of magnetic resonance imaging in low-dose-rate and high-dose-rate prostate brachytherapy from diagnosis to treatment assessment: Defining the knowledge gaps, technical challenges, and barriers to implementation. <i>Brachytherapy</i> , 2017, 16, 672-678.	0.5	15
192	Clinical outcomes after local field conformal reirradiation of patients with retropharyngeal nodal metastasis. <i>Head and Neck</i> , 2017, 39, 2079-2087.	2.0	15
193	Development and clinical implementation of SeedNet: A slidingâ€“window convolutional neural network for radioactive seed identification in MRIâ€“assisted radiosurgery (MARS). <i>Magnetic Resonance in Medicine</i> , 2019, 81, 3888-3900.	3.0	15
194	Combined Inhibition of Rad51 and Wee1 Enhances Cell Killing in HNSCC Through Induction of Apoptosis Associated With Excessive DNA Damage and Replication Stress. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1257-1269.	4.1	15
195	Stereotactic body ablative radiotherapy for reirradiation of small volume head and neck cancers is associated with prolonged survival: Large, singleâ€“institution, modern cohort study. <i>Head and Neck</i> , 2021, 43, 3331-3344.	2.0	15
196	ACR Appropriateness Criteriaâ„® Postradical Prostatectomy Irradiation in Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 92-98.	1.3	14
197	Sexual potency preservation and quality of life after prostate brachytherapy and low-dose tadalafil. <i>Brachytherapy</i> , 2015, 14, 160-165.	0.5	14
198	Outcomes for hypopharyngeal carcinoma treated with organâ€“preservation therapy. <i>Head and Neck</i> , 2016, 38, E2091-9.	2.0	14

#	ARTICLE	IF	CITATIONS
199	Pulse sequence considerations for simulation and postimplant dosimetry of prostate brachytherapy. <i>Brachytherapy</i> , 2017, 16, 743-753.	0.5	14
200	Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching "liquid biopsy" and quantitative tumor modeling. <i>BMC Cancer</i> , 2018, 18, 903.	2.6	14
201	Fixed- versus Variable-RBE Computations for Intensity Modulated Proton Therapy. <i>Advances in Radiation Oncology</i> , 2019, 4, 156-167.	1.2	14
202	A prospective longitudinal assessment of MRI signal intensity kinetics of non-target muscles in patients with advanced stage oropharyngeal cancer in relationship to radiotherapy dose and post-treatment radiation-associated dysphagia: Preliminary findings from a randomized trial. <i>Radiotherapy and Oncology</i> , 2019, 130, 46-55.	0.6	14
203	Radiation-Induced Hypothyroidism After Radical Intensity Modulated Radiation Therapy for Oropharyngeal Carcinoma. <i>Advances in Radiation Oncology</i> , 2020, 5, 111-119.	1.2	14
204	<scp>Highly conformal</scp> reirradiation in patients with prior oropharyngeal radiation: Clinical efficacy and toxicity outcomes. <i>Head and Neck</i> , 2020, 42, 3326-3335.	2.0	14
205	Proton Beam Therapy for Localized Prostate Cancer: Results from a Prospective Quality-of-Life Trial. <i>International Journal of Particle Therapy</i> , 2016, 3, 27-36.	1.8	14
206	Primary intestinal-like adenocarcinoma of major salivary glands: 2 instances of previously undocumented phenotype. <i>Head and Neck</i> , 2013, 35, E234-6.	2.0	13
207	A novel dose-based positioning method for CT image-guided proton therapy. <i>Medical Physics</i> , 2013, 40, 051714.	3.0	13
208	ACR Appropriateness Criteria® Definitive External-Beam Irradiation in Stage T1 and T2 Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 278-288.	1.3	13
209	Characteristics and kinetics of cervical lymph node regression after radiation therapy for human papillomavirus-associated oropharyngeal carcinoma: Quantitative image analysis of post-radiotherapy response. <i>Oral Oncology</i> , 2015, 51, 195-201.	1.5	13
210	Early Stage olfactory neuroblastoma and the impact of resecting dura and olfactory bulb. <i>Laryngoscope</i> , 2018, 128, 1274-1280.	2.0	13
211	The effects of zinc on radiation-induced dysgeusia: a systematic review and meta-analysis. <i>Supportive Care in Cancer</i> , 2020, 28, 1-12.	2.2	13
212	Predictors of urinary toxicity with MRI-assisted radiosurgery for low-dose-rate prostate brachytherapy. <i>Brachytherapy</i> , 2020, 19, 574-583.	0.5	13
213	Evaluation of the accuracy of deformable image registration on MRI with a physical phantom. <i>Journal of Applied Clinical Medical Physics</i> , 2020, 21, 166-173.	1.9	13
214	Biology of the Radio- and Chemo-Responsiveness in HPV Malignancies. <i>Seminars in Radiation Oncology</i> , 2021, 31, 274-285.	2.2	13
215	Outcomes and Toxicities of Proton and Photon Radiation Therapy for Testicular Seminoma. <i>International Journal of Particle Therapy</i> , 2020, 7, 11-20.	1.8	13
216	Anisotropy Characterization of I-125 Seed with Attached Encapsulated Cobalt Chloride Complex Contrast Agent Markers for MRI-Based Prostate Brachytherapy. <i>Medical Dosimetry</i> , 2011, 36, 200-205.	0.9	12

#	ARTICLE	IF	CITATIONS
217	Knife or needles? A cohort analysis of outcomes after radical prostatectomy or brachytherapy for men with low- or intermediate-risk adenocarcinoma of the prostate. <i>Brachytherapy</i> , 2012, 11, 429-434.	0.5	12
218	Biological responses of human solid tumor cells to X-ray irradiation within a 1.5-Tesla magnetic field generated by a magnetic resonance imaging-linear accelerator. <i>Bioelectromagnetics</i> , 2016, 37, 471-480.	1.6	12
219	Patient-reported health-related quality of life for men treated with low-dose-rate prostate brachytherapy as monotherapy with 125-iodine, 103-palladium, or 131-caesium: Results of a prospective phase II study. <i>Brachytherapy</i> , 2018, 17, 265-276.	0.5	12
220	Characterization of a new physical phantom for testing rigid and deformable image registration. <i>Journal of Applied Clinical Medical Physics</i> , 2019, 20, 145-153.	1.9	12
221	Minocycline for symptom reduction during radiation therapy for head and neck cancer: a randomized clinical trial. <i>Supportive Care in Cancer</i> , 2020, 28, 261-269.	2.2	12
222	Estimating PTV Margins in Head and Neck Stereotactic Ablative Radiation Therapy (SABR) Through Target Site Analysis of Positioning and Intrafractional Accuracy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 185-193.	0.8	12
223	Developing an intraoperative 3T MRI-guided brachytherapy program within a diagnostic imaging suite: Methods, process workflow, and value-based analysis. <i>Brachytherapy</i> , 2020, 19, 427-437.	0.5	12
224	Outcomes after salvage for HPV-positive recurrent oropharyngeal cancer treated with primary radiation. <i>Oral Oncology</i> , 2021, 113, 105125.	1.5	12
225	Non-canonical function of DCCR8 in DNA double-strand break repair signaling and tumor radioresistance. <i>Nature Communications</i> , 2021, 12, 4033.	12.8	12
226	Bioelectrical impedance analysis as a quantitative measure of sarcopenia in head and neck cancer patients treated with radiotherapy. <i>Radiotherapy and Oncology</i> , 2021, 159, 21-27.	0.6	12
227	Lyman-Kutcher-Burman normal tissue complication probability modeling for radiation-induced esophagitis in non-small cell lung cancer patients receiving proton radiotherapy. <i>Radiotherapy and Oncology</i> , 2020, 146, 200-204.	0.6	12
228	Dosimetric impact of fiducial markers in patients undergoing photon beam radiation therapy. <i>Physica Medica</i> , 2012, 28, 240-244.	0.7	11
229	Comparison of systemic therapies used concurrently with radiation for the treatment of human papillomavirus-associated oropharyngeal cancer. <i>Head and Neck</i> , 2016, 38, E1554-61.	2.0	11
230	Patterns of protein expression in human head and neck cancer cell lines differ after proton vs photon radiotherapy. <i>Head and Neck</i> , 2020, 42, 289-301.	2.0	11
231	The impact of tongue-deviating and tongue-depressing oral stents on long-term radiation-associated symptoms in oropharyngeal cancer survivors. <i>Clinical and Translational Radiation Oncology</i> , 2020, 24, 71-78.	1.7	11
232	Prospective longitudinal patient-reported outcomes of swallowing following intensity modulated proton therapy for oropharyngeal cancer. <i>Radiotherapy and Oncology</i> , 2020, 148, 133-139.	0.6	11
233	Stereotactic Body Radiation Therapy for the Definitive Treatment of Early Stage Kidney Cancer: A Survival Comparison With Surgery, Tumor Ablation, and Observation. <i>Advances in Radiation Oncology</i> , 2020, 5, 495-502.	1.2	11
234	Proton Therapy for HPV-Associated Oropharyngeal Cancers of the Head and Neck: a De-Intensification Strategy. <i>Current Treatment Options in Oncology</i> , 2021, 22, 54.	3.0	11

#	ARTICLE	IF	CITATIONS
235	Work Outcomes after Intensity-Modulated Proton Therapy (IMPT) versus Intensity-Modulated Photon Therapy (IMRT) for Oropharyngeal Cancer. <i>International Journal of Particle Therapy</i> , 2021, 8, 319-327.	1.8	11
236	Development, implementation, and outcomes of a simulation-based medical education (SBME) prostate brachytherapy workshop for radiation oncology residents. <i>Brachytherapy</i> , 2020, 19, 738-745.	0.5	11
237	Sexual Function and the Use of Medical Devices or Drugs to Optimize Potency After Prostate Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, e765-e771.	0.8	10
238	ACR Appropriateness Criteria® External-Beam Radiation Therapy Treatment Planning for Clinically Localized Prostate Cancer. <i>Journal of the American College of Radiology</i> , 2012, 9, 233-238.	1.8	10
239	Metabolic Imaging as a Biomarker of Early Radiation Response in Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 4996-4998.	7.0	10
240	Orbital carcinomas treated with adjuvant intensity-modulated radiation therapy. <i>Head and Neck</i> , 2016, 38, E580-7.	2.0	10
241	Second salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer. <i>Journal of Contemporary Brachytherapy</i> , 2017, 2, 161-166.	0.9	10
242	Outcomes and patterns of radiation associated brain image changes after proton therapy for head and neck skull base cancers. <i>Radiotherapy and Oncology</i> , 2020, 151, 119-125.	0.6	10
243	Developing a Value Framework: Utilizing Administrative Data to Assess an Enhanced Care Initiative. <i>Journal of Surgical Research</i> , 2021, 262, 115-120.	1.6	10
244	The Role of Particle Therapy in Adenoid Cystic Carcinoma and Mucosal Melanoma of the Head and Neck. <i>International Journal of Particle Therapy</i> , 2021, 8, 273-284.	1.8	10
245	The Biological Basis for Enhanced Effects of Proton Radiation Therapy Relative to Photon Radiation Therapy for Head and Neck Squamous Cell Carcinoma. <i>International Journal of Particle Therapy</i> , 2021, 8, 3-13.	1.8	10
246	Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified. <i>Cancer</i> , 2022, 128, 509-518.	4.1	10
247	Treatment of recurrent vaginal melanoma with external beam radiation therapy and palladium-103 brachytherapy. <i>Brachytherapy</i> , 2008, 7, 359-363.	0.5	9
248	Evaluation of the MIM Symphony treatment planning system for low-dose-rate prostate brachytherapy. <i>Journal of Applied Clinical Medical Physics</i> , 2015, 16, 62-75.	1.9	9
249	Prostate brachytherapy, either alone or in combination with external beam radiation, is associated with longer overall survival in men with favorable pathologic Group 4 (Gleason score 8) prostate cancer. <i>Brachytherapy</i> , 2017, 16, 790-796.	0.5	9
250	Permanent prostate brachytherapy postimplant magnetic resonance imaging dosimetry using positive contrast magnetic resonance imaging markers. <i>Brachytherapy</i> , 2017, 16, 761-769.	0.5	9
251	Parallel imaging compressed sensing for accelerated imaging and improved signal-to-noise ratio in MRI-based postimplant dosimetry of prostate brachytherapy. <i>Brachytherapy</i> , 2018, 17, 816-824.	0.5	9
252	Development of a stereoscopic CT metal artifact management algorithm using gantry angle tilts for head and neck patients. <i>Journal of Applied Clinical Medical Physics</i> , 2020, 21, 120-130.	1.9	9

#	ARTICLE	IF	CITATIONS
253	The American Brachytherapy Society prostate brachytherapy LDR/HDR simulation workshops: Hands-on, step-by-step training in the process of quality assurance. <i>Brachytherapy</i> , 2020, 19, 787-793.	0.5	9
254	Comparison of tumor delineation using dual energy computed tomography versus magnetic resonance imaging in head and neck cancer re-irradiation cases. <i>Physics and Imaging in Radiation Oncology</i> , 2020, 14, 1-5.	2.9	9
255	Three-Year Results of a Prospective Statewide Insurance Coverage Pilot for Proton Therapy: Stakeholder Collaboration Improves Patient Access to Care. <i>JCO Oncology Practice</i> , 2020, 16, e966-e976.	2.9	9
256	NTCP Modeling of Late Effects for Head and Neck Cancer: A Systematic Review. <i>International Journal of Particle Therapy</i> , 2021, 8, 95-107.	1.8	9
257	Communicating Value: Use of a Novel Framework in the Assessment of an Enhanced Recovery Initiative. <i>Annals of Surgery</i> , 2021, 273, e7-e9.	4.2	9
258	Screening colonoscopy before prostate cancer treatment can detect colorectal cancers in asymptomatic patients and reduce the rate of complications after brachytherapy. <i>Practical Radiation Oncology</i> , 2012, 2, e7-e13.	2.1	8
259	Advances in Radiation Oncology for the Management of Oropharyngeal Tumors. <i>Otolaryngologic Clinics of North America</i> , 2013, 46, 629-643.	1.1	8
260	Dosimetric influence of seed spacers and end-weld thickness for permanent prostate brachytherapy. <i>Brachytherapy</i> , 2014, 13, 304-310.	0.5	8
261	Patterns of locoregional failure following post-operative intensity-modulated radiotherapy to oral cavity cancer: quantitative spatial and dosimetric analysis using a deformable image registration workflow. <i>Radiation Oncology</i> , 2017, 12, 129.	2.7	8
262	Surveillance imaging for patients with head and neck cancer treated with definitive radiotherapy: A partially observed Markov decision process model. <i>Cancer</i> , 2020, 126, 749-756.	4.1	8
263	Patterns of Failure After Intensity Modulated Radiation Therapy in Head and Neck Squamous Cell Carcinoma of Unknown Primary: Implication of Elective Nodal and Mucosal Dose Coverage. <i>Advances in Radiation Oncology</i> , 2020, 5, 929-935.	1.2	8
264	Proton Therapy for Head and Neck Cancer: A 12-Year, Single-Institution Experience. <i>International Journal of Particle Therapy</i> , 2021, 8, 108-118.	1.8	8
265	Hydrogel Spacer Reduces Rectal Dose during Proton Therapy for Prostate Cancer: A Dosimetric Analysis. <i>International Journal of Particle Therapy</i> , 2019, 5, 23-31.	1.8	8
266	Prostogram Predicted Brachytherapy Outcomes are Not Universally Accurate: An Analysis Based on the M. D. Anderson Cancer Center Experience With 125 Iodine Brachytherapy. <i>Journal of Urology</i> , 2009, 181, 1658-1664.	0.4	7
267	Displacement of periurethral stranded seeds and its dosimetric consequences in prostate brachytherapy. <i>Brachytherapy</i> , 2011, 10, 401-408.	0.5	7
268	Clinical Investigations Long-term tumor control after brachytherapy for base of prostate cancer. <i>Journal of Contemporary Brachytherapy</i> , 2011, 4, 183-187.	0.9	7
269	Intensity Modulated Proton Therapy for Head and Neck Tumors: Gilding the Lily or Holy Grail?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 37-39.	0.8	7
270	Comparison of prostate distortion by inflatable and rigid endorectal MRI coils in permanent prostate brachytherapy imaging. <i>Brachytherapy</i> , 2018, 17, 298-305.	0.5	7

#	ARTICLE	IF	CITATIONS
271	Patient Outcomes after Reirradiation of Small Skull Base Tumors using Stereotactic Body Radiotherapy, Intensity Modulated Radiotherapy, or Proton Therapy. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2020, 81, 638-644.	0.8	7
272	Quality comparison between three-dimensional T2-weighted SPACE and two-dimensional T2-weighted turbo spin echo magnetic resonance images for the brachytherapy planning evaluation of prostate and periprostatic anatomy. <i>Brachytherapy</i> , 2020, 19, 484-490.	0.5	7
273	A Dosimetric Comparison of Oral Cavity Sparing in the Unilateral Treatment of Early Stage Tonsil Cancer: IMRT, IMPT, and Tongue-Deviating Oral Stents. <i>Advances in Radiation Oncology</i> , 2020, 5, 1359-1363.	1.2	7
274	Longitudinal characterization of the tumoral microbiome during radiotherapy in HPV-associated oropharynx cancer. <i>Clinical and Translational Radiation Oncology</i> , 2021, 26, 98-103.	1.7	7
275	Evaluation of image quality of a novel computed tomography metal artifact management technique on an anthropomorphic head and neck phantom. <i>Physics and Imaging in Radiation Oncology</i> , 2021, 17, 111-116.	2.9	7
276	Fully Balanced SSFP Without an Endorectal Coil for Postimplant QA of MRI-Assisted Radiosurgery (MARS) of Prostate Cancer: A Prospective Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 614-625.	0.8	7
277	Robust Optimization for Intensity Modulated Proton Therapy Plans with Multi-Isocenter Large Fields. <i>International Journal of Particle Therapy</i> , 2016, 3, 305-311.	1.8	7
278	A Volumetric Trend Analysis of the Prostate and Seminal Vesicles During a Course of Intensity-Modulated Radiation Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 173-175.	1.3	7
279	Prospective Evaluation of Prostate and Organs at Risk Segmentation Software for MRI-based Prostate Radiation Therapy. <i>Radiology: Artificial Intelligence</i> , 2022, 4, e210151.	5.8	7
280	Computer-aided segmentation on MRI for prostate radiotherapy, Part I: Quantifying human interobserver variability of the prostate and organs at risk and its impact on radiation dosimetry. <i>Radiotherapy and Oncology</i> , 2022, 169, 124-131.	0.6	7
281	Preoperative treatment planning with intraoperative optimization can achieve consistent high-quality implants in prostate brachytherapy. <i>Medical Dosimetry</i> , 2012, 37, 387-390.	0.9	6
282	MRI-based sector analysis enhances prostate palladium-103 brachytherapy quality assurance in a phase II prospective trial of men with intermediate-risk localized prostate cancer. <i>Brachytherapy</i> , 2014, 13, 68-74.	0.5	6
283	Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancer. <i>Oral Oncology</i> , 2018, 79, 1-8.	1.5	6
284	Stereotactic radiosurgery for trigeminal pain secondary to recurrent malignant skull base tumors. <i>Journal of Neurosurgery</i> , 2019, 130, 812-821.	1.6	6
285	Transitioning from measurement-based to combined patient-specific quality assurance for intensity-modulated proton therapy. <i>British Journal of Radiology</i> , 2020, 93, 20190669.	2.2	6
286	Strategic Operational Redesign for Successfully Navigating Prior Authorization Barriers at a Large-Volume Proton Therapy Center. <i>JCO Oncology Practice</i> , 2020, 16, e1067-e1077.	2.9	6
287	A prospective parallel design study testing non-inferiority of customized oral stents made using 3D printing or manually fabricated methods. <i>Oral Oncology</i> , 2020, 106, 104665.	1.5	6
288	Data from a terminated study on iron oxide nanoparticle magnetic resonance imaging for head and neck tumors. <i>Scientific Data</i> , 2020, 7, 63.	5.3	6

#	ARTICLE	IF	CITATIONS
289	Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores – A pooled analysis of RTOG 0129 and 0522. <i>Oral Oncology</i> , 2021, 116, 105241.	1.5	6
290	Financial Toxicity in Head and Neck Cancer Patients Treated With Proton Therapy. <i>International Journal of Particle Therapy</i> , 2021, 8, 366-373.	1.8	6
291	18FDG positron emission tomography mining for metabolic imaging biomarkers of radiation-induced xerostomia in patients with oropharyngeal cancer. <i>Clinical and Translational Radiation Oncology</i> , 2021, 29, 93-101.	1.7	6
292	Referral Patterns and Treatment Delays in Medulloblastoma: A Large Academic Proton Center Experience. <i>International Journal of Particle Therapy</i> , 2021, 7, 1-10.	1.8	6
293	Unilateral Radiotherapy for Tonsillar Cancer: Treatment Outcomes in the Era of Human Papilloma Virus (HPV), Positron-emission Tomography (PET) and Intensity-modulated Radiation Therapy (IMRT). <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, , .	0.8	6
294	Advances in Radiation Treatments of Breast Cancer. <i>Clinical Breast Cancer</i> , 2004, 4, 401-406.	2.4	5
295	Update on Radiation Therapy in Prostate Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2006, 20, 857-878.	2.2	5
296	Multidisciplinary Management of Primary Adenoid Cystic Carcinoma of the Eyelid With Perineural Invasion. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2013, 29, e143-e146.	0.8	5
297	Proton therapy for seminoma: Case report describing the technique, efficacy, and advantages of proton-based therapy for seminoma. <i>Practical Radiation Oncology</i> , 2015, 5, 135-140.	2.1	5
298	Bending the slope of the brachytherapy curve: Magnetic resonance imaging-assisted radiosurgery for the treatment of prostate cancer. <i>Brachytherapy</i> , 2017, 16, 657-658.	0.5	5
299	MRI-Based Prostate Brachytherapy - Imaging with and without an Endorectal Coil for Post-Implant Quality Assurance. <i>Brachytherapy</i> , 2017, 16, S56.	0.5	5
300	Cognitive function and patient-reported memory problems after radiotherapy for cancers at the skull base: A cross-sectional survivorship study using the Telephone Interview for Cognitive Status and the MD Anderson Symptom Inventory-Head and Neck Module. <i>Head and Neck</i> , 2017, 39, 2048-2056.	2.0	5
301	The Potential of Heavy-Ion Therapy to Improve Outcomes for Locally Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 201.	2.8	5
302	Deep learning application engine (DLAE): Development and integration of deep learning algorithms in medical imaging. <i>SoftwareX</i> , 2019, 10, 100347.	2.6	5
303	Costs and Complications After a Diagnosis of Prostate Cancer Treated With Time-Efficient Modalities: An Analysis of National Medicare Data. <i>Practical Radiation Oncology</i> , 2020, 10, 282-292.	2.1	5
304	Prospective observational evaluation of radiation-induced late taste impairment kinetics in oropharyngeal cancer patients: Potential for improvement over time?. <i>Clinical and Translational Radiation Oncology</i> , 2020, 22, 98-105.	1.7	5
305	Outcomes of patients with oropharyngeal squamous cell carcinoma treated with induction chemotherapy followed by concurrent chemoradiation compared with those treated with concurrent chemoradiation. <i>Cancer</i> , 2021, 127, 2916-2925.	4.1	5
306	Cost-Effectiveness Models of Proton Therapy for Head and Neck: Evaluating Quality and Methods to Date. <i>International Journal of Particle Therapy</i> , 2021, 8, 339-353.	1.8	5

#	ARTICLE	IF	CITATIONS
307	A Review of Particle Therapy for Skull Base Tumors: Modern Considerations and Future Directions. International Journal of Particle Therapy, 2021, 8, 168-178.	1.8	5
308	PROSTATE BRACHYTHERAPY – THE M.D. ANDERSON CANCER CENTER EXPERIENCE. Journal of Urology, 2008, 179, 396-397.	0.4	4
309	Impact of urinary catheterization on dosimetry after prostate implant brachytherapy with palladium-103 or iodine-125. Brachytherapy, 2011, 10, 269-274.	0.5	4
310	Oncology Scan – Demonstrating Technology and Measuring Outcomes in Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 88, 759-760.	0.8	4
311	Permanent prostate brachytherapy pubic arch evaluation with diagnostic magnetic resonance imaging. Brachytherapy, 2017, 16, 728-733.	0.5	4
312	Synchrotron-Based Pencil Beam Scanning Nozzle with an Integrated Mini-Ridge Filter: A Dosimetric Study to Optimize Treatment Delivery. Cancers, 2017, 9, 170.	3.7	4
313	Evaluating single-institution resource costs of consolidative radiotherapy for oligometastatic non-small cell lung cancer using time-driven activity-based costing. Clinical and Translational Radiation Oncology, 2020, 23, 80-84.	1.7	4
314	Development and validation of a contouring guideline for the taste bud bearing tongue mucosa. Radiotherapy and Oncology, 2021, 157, 63-69.	0.6	4
315	Proton Therapy for Major Salivary Gland Cancer: Clinical Outcomes. International Journal of Particle Therapy, 2021, 8, 261-272.	1.8	4
316	Proton Beam Therapy for Head and Neck Carcinoma of Unknown Primary: Toxicity and Quality of Life. International Journal of Particle Therapy, 2021, 8, 234-247.	1.8	4
317	Proton Radiotherapy to Reduce Late Complications in Childhood Head and Neck Cancers. International Journal of Particle Therapy, 2021, 8, 155-167.	1.8	4
318	Activity-Based Costing of Intensity-Modulated Proton versus Photon Therapy for Oropharyngeal Cancer. International Journal of Particle Therapy, 2021, 8, 374-382.	1.8	4
319	Variations in Proton Therapy Coverage in the State of Texas: Defining Medical Necessity for a Safe and Effective Treatment. International Journal of Particle Therapy, 2016, 2, 499-508.	1.8	4
320	Predictive performance of different NTCP techniques for radiation-induced esophagitis in NSCLC patients receiving proton radiotherapy. Scientific Reports, 2022, 12, .	3.3	4
321	ACR Appropriateness Criteria® Definitive External Beam Irradiation in Stage T1 and T2 Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 636-647.	1.3	3
322	MRI Image-Guided Low-Dose Rate Brachytherapy for Prostate Cancer. , 2017, , 319-344.		3
323	SeedNet for Automated Detection and Localization of Radioactive Seeds in Post-Implant MRI: A Comparison with and without the use of An Endorectal Coil for Imaging. Brachytherapy, 2018, 17, S80-S81.	0.5	3
324	Reactive Oxygen Species Generation in Human Cells by a Novel Magnetic Resonance Imaging Contrast Agent. Journal of Toxicology, 2018, 2018, 1-7.	3.0	3

#	ARTICLE	IF	CITATIONS
325	Multi-Tasking Neural Networks for Anatomy Segmentation in Prostate Brachytherapy MRI. <i>Brachytherapy</i> , 2019, 18, S16.	0.5	3
326	MRI-assisted radiosurgery: A quality assurance nomogram for palladium-103 and iodine-125 prostate brachytherapy. <i>Brachytherapy</i> , 2020, 19, 38-42.	0.5	3
327	A prospective evaluation of health-related quality of life after skull base re-irradiation. <i>Head and Neck</i> , 2020, 42, 485-497.	2.0	3
328	Evaluation of the high definition field of view option of a large-bore computed tomography scanner for radiation therapy simulation. <i>Physics and Imaging in Radiation Oncology</i> , 2020, 13, 44-49.	2.9	3
329	Neurologic sequelae following radiation with and without chemotherapy for oropharyngeal cancer: Patient reported outcomes study. <i>Head and Neck</i> , 2020, 42, 2137-2144.	2.0	3
330	SABR for Skull Base Malignancies: A Systematic Analysis of Set-Up and Positioning Accuracy. <i>Practical Radiation Oncology</i> , 2020, 10, 363-371.	2.1	3
331	Dosimetric impact of commercial CT metal artifact reduction algorithms and a novel in-house algorithm for proton therapy of head and neck cancer. <i>Medical Physics</i> , 2021, 48, 445-455.	3.0	3
332	The Reality of Randomized Controlled Trials for Assessing the Benefit of Proton Therapy: Critically Examining the Intent-to-Treat Principle in the Presence of Insurance Denial. <i>Advances in Radiation Oncology</i> , 2021, 6, 100635.	1.2	3
333	PTCOG Head and Neck Subcommittee Consensus Guidelines on Particle Therapy for the Management of Head and Neck Tumors. <i>International Journal of Particle Therapy</i> , 2021, 8, 84-94.	1.8	3
334	Proton Therapy in a Pandemic: An Operational Response to the COVID-19 Crisis. <i>International Journal of Particle Therapy</i> , 2020, 7, 54-57.	1.8	3
335	American Brachytherapy Society radiation oncology alternative payment model task force: Quality measures and metrics for brachytherapy. <i>Brachytherapy</i> , 2022, 21, 63-74.	0.5	3
336	Risk stratification after recurrence of human papillomavirus (HPV) related and non-HPV related oropharyngeal cancer: A secondary analysis of NRG Oncology RTOG 0129 and 0522. <i>Head and Neck</i> , 2021, 44, 158.	2.0	3
337	Proton Image-guided Radiation Assignment for Therapeutic Escalation via Selection of locally advanced head and neck cancer patients [PIRATES]: A Phase I safety and feasibility trial of MRI-guided adaptive particle radiotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2022, 32, 35-40.	1.7	3
338	Computer-aided segmentation on MRI for prostate radiotherapy, part II: Comparing human and computer observer populations and the influence of annotator variability on algorithm variability. <i>Radiotherapy and Oncology</i> , 2022, 169, 132-139.	0.6	3
339	Early Quality of Life Outcomes for MRI-Assisted Prostate Brachytherapy Patients. <i>Brachytherapy</i> , 2017, 16, S108.	0.5	2
340	Automated Prostate Brachytherapy Seed Detection on Post-Implant MRI Using Novel Martin Algorithm. <i>Brachytherapy</i> , 2017, 16, S57.	0.5	2
341	A Dosimetric Comparison of Oral Cavity Sparing in the Unilateral Treatment of Early Stage Tonsil Cancer: IMRT, IMPT, and Tongue Deviating Oral Stents. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, E36.	0.8	2
342	Defining the Value of MRI-Assisted Radiosurgery (MARS) for Prostate Brachytherapy: A Pilot Study Using Time-Driven Activity-Based Costing. <i>Brachytherapy</i> , 2019, 18, S80.	0.5	2

#	ARTICLE	IF	CITATIONS
343	Optimizing laryngeal sparing with intensity modulated radiotherapy or volumetric modulated arc therapy for unilateral tonsil cancer. <i>Physics and Imaging in Radiation Oncology</i> , 2019, 10, 29-34.	2.9	2
344	Conditional survival among patients with oropharyngeal cancer treated with radiation therapy and alive without recurrence 5 years after diagnosis. <i>Cancer</i> , 2021, 127, 1228-1237.	4.1	2
345	Patient-Reported Outcomes after Intensity-Modulated Proton Therapy for Oropharynx Cancer. <i>International Journal of Particle Therapy</i> , 2021, 8, 213-222.	1.8	2
346	Improving efficiency and reducing costs of MRI-Guided prostate brachytherapy using Time-Driven Activity-Based costing. <i>Brachytherapy</i> , 2022, 21, 49-54.	0.5	2
347	Novel Hybrid Scattering- and Scanning-Beam Proton Therapy Approach. <i>International Journal of Particle Therapy</i> , 2016, 3, 37-50.	1.8	2
348	Self-Referral: What Residents Need To Know. <i>Journal of the American College of Radiology</i> , 2005, 2, 452-454.	1.8	1
349	The Influence of Age and Comorbidity on the Benefit of Adding Androgen Deprivation to Dose-escalated Radiation in Men With Intermediate-risk Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 368-373.	1.3	1
350	Permanent Seed Implantation Prostate Brachytherapy for Intermediate Risk Prostate Cancer: Efficacy and Toxicity Outcomes from a Prospective Cohort of 300 Patients. <i>Brachytherapy</i> , 2016, 15, S201.	0.5	1
351	Reply to radiotherapy for human papillomavirus-positive oropharyngeal cancers in the National Cancer Data Base. <i>Cancer</i> , 2016, 122, 3411-3412.	4.1	1
352	2017 American Brachytherapy Society's Annual Meeting Report. <i>Translational Andrology and Urology</i> , 2017, 6, 1005-1013.	1.4	1
353	A Prospective Trial Evaluating Patient Reported Outcomes of Customized Oral Stents for Head and Neck (HN) Radiotherapy (RT) Using 3D Printing and Traditional Methods. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, E35-E36.	0.8	1
354	Principles of radiobiology. , 2021, , 1-13.e6.		1
355	The influence of radiation dose on taste impairment in a prospective observational study cohort of oropharyngeal cancer patients. <i>Acta Oncologica</i> , 2022, 61, 146-152.	1.8	1
356	Health Care Resource Utilization for Esophageal Cancer Using Proton versus Photon Radiation Therapy. <i>International Journal of Particle Therapy</i> , 2022, 9, 18-27.	1.8	1
357	Heterogeneous planning for homogeneous protocols. <i>Medical Dosimetry</i> , 2004, 29, 80-84.	0.9	0
358	Radiation Therapy for Orbital and Adnexal Tumors. , 2010, , 169-175.		0
359	Subacute penile numbness after brachytherapy for prostate cancer. <i>Brachytherapy</i> , 2011, 10, 64-67.	0.5	0
360	Response to Drs Rogers, Hayes, and Demanes. <i>Brachytherapy</i> , 2014, 13, 523-525.	0.5	0

#	ARTICLE	IF	CITATIONS
361	Outcomes after adjuvant radiation therapy for prostate cancer at a comprehensive cancer center. Journal of Radiation Oncology, 2016, 5, 287-292.	0.7	0
362	In Reply to Yamazaki etÂal. International Journal of Radiation Oncology Biology Physics, 2017, 97, 868-869.	0.8	0
363	Toxicity Evaluation of a Novel Magnetic Resonance Imaging Marker, CoCl2-N-Acetylcysteine, in Rats. Journal of Toxicology, 2018, 2018, 1-8.	3.0	0
364	Long-term Outcomes of Globe-Preserving Surgery with Proton Beam Radiation for Adenoid Cystic Carcinoma of the Lacrimal Gland. American Journal of Ophthalmology, 2019, 201, 83-84.	3.3	0
365	Technological advancements and outlook in proton therapy. , 2021, , 215-220.e5.		0
366	The University of Texas MD Anderson cancer centerâ€™s recommended proton therapy indications. , 2021, , 221-250.		0
367	Effect of adding short-term androgen deprivation therapy to dose-escalated radiation therapy on failure-free survival for select men with intermediate-risk prostate cancer.. Journal of Clinical Oncology, 2012, 30, 176-176.	1.6	0
368	TU-G-134-05: MRI Characteristics of Cobalt Dichloride N-Acetyl Cysteine (C4) as a Contrast Agent Marker for Prostate Brachytherapy. Medical Physics, 2013, 40, 461-461.	3.0	0
369	Driving accountable care with brachytherapy. Brachytherapy, 2022, 21, 4-5.	0.5	0